TM38837

Research use only, not for human use.

TM38837 is an antagonist of cannabinoid receptor type 1 (CB1), with potential for the treatment of obesity and type 2 diabetes.

TM38837 is an antagonist of cannabinoid receptor type 1 (CB1), with potential for the treatment of obesity and type 2 diabetes. TM38837, a novel, largely peripherally restricted CB1 antagonist, in terms of fear-promoting consequences of systemic vs. intracerebral injections.?Different groups of male C57BL/6 N mice underwent auditory fear conditioning, followed by re-exposure to the tone.?Mice were treated per os (p.o.) with TM38837 (10, 30, or 100 mg/kg), rimonabant (10 mg/kg;?a brain penetrating CB1 antagonist/inverse agonist which served as a positive control), or vehicle, 2 h prior the tone presentation.?Only the high dose of TM38837 (100 mg/kg) induced a significant increase in freezing behavior, similar to that induced by rimonabant (10 mg/kg) (p

——

CB1 antagonist 4 (compound 8) (10-100 mg/kg; p.o.) induces a significant increase in freezing behavior at 100 mg/kg. Animal Model:7-8 weeks old male C57BL/6 N mice (B6N) Dosage:10, 30, or 100 mg/kg Administration:p.o.Result:High dose (100 mg/kg) induced a significant increase in freezing behavior.

——

GPCR/G Protein

Cannabinoid Receptor

CB1

——

——

1253641-65-4

617.51

C30H25Cl2F3N4OS

>98% (HPLC)

DMSO:40 mg/mL (64.77 mM; Need ultrasonic)

CCC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(S1)C#CC1=CC=C(C=C1)C(F)(F)F

——

(-20℃)

With Ice Pack

≥ 2 years